C4 Therapeutics, Inc. (NASDAQ:CCCC) Shares Sold by Arete Wealth Advisors LLC

Arete Wealth Advisors LLC decreased its holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC) by 34.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 73,350 shares of the company’s stock after selling 37,950 shares during the quarter. Arete Wealth Advisors LLC’s holdings in C4 Therapeutics were worth $418,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Point72 DIFC Ltd acquired a new position in C4 Therapeutics in the 3rd quarter worth about $51,000. Headlands Technologies LLC acquired a new position in shares of C4 Therapeutics during the second quarter valued at approximately $45,000. Cynosure Group LLC acquired a new position in shares of C4 Therapeutics during the third quarter valued at approximately $57,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of C4 Therapeutics during the second quarter valued at approximately $51,000. Finally, Aigen Investment Management LP acquired a new position in shares of C4 Therapeutics during the third quarter valued at approximately $82,000. Institutional investors and hedge funds own 78.81% of the company’s stock.

C4 Therapeutics Price Performance

CCCC stock opened at $4.32 on Friday. The business has a 50 day simple moving average of $5.19 and a 200-day simple moving average of $5.48. The firm has a market capitalization of $304.94 million, a PE ratio of -2.54 and a beta of 2.92. C4 Therapeutics, Inc. has a 1 year low of $3.16 and a 1 year high of $11.88.

C4 Therapeutics (NASDAQ:CCCC) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.05. The business had revenue of $15.36 million during the quarter, compared to analyst estimates of $5.95 million. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. On average, equities research analysts expect that C4 Therapeutics, Inc. will post -1.52 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Stephens started coverage on C4 Therapeutics in a report on Monday, November 18th. They set an “equal weight” rating and a $4.00 target price for the company. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $10.00.

C4 Therapeutics Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.